Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3911950 | 0.95 | MAOA (0.46) | MAOAMAOBTSHRMEN1GAA | |
| SCHEMBL22996130 | 0.93 | MAOA (0.49) | MAOAMAOBTSHRMEN1KMT2A | |
| SCHEMBL2137955 | 0.89 | MAOA (0.44) | MAOAMAOBTSHRMEN1GAA | |
| SCHEMBL756032 | 0.89 | MAOA (0.39) | MAOAMAOBTSHRMEN1GAA | |
| SCHEMBL9891443 | 0.89 | MAOA (0.46) | MAOAMAOBTSHRMEN1GAA | |
| SCHEMBL7432213 | 0.86 | TSHR (0.48) | MAOAMAOBTSHRTDP1LMNA | |
| SCHEMBL10727964 | 0.83 | MAOA (0.49) | MAOAMAOBTSHRADRA1ATDP1 | |
| SCHEMBL2135566 | 0.83 | MAOA (0.49) | MAOAMAOBTSHRADRA1ATDP1 | |
| SCHEMBL397677 | 0.83 | CA2 (0.37) | MAOAMAOBTSHRMEN1GAA | |
| SCHEMBL6535041 | 0.82 | MAOA (0.44) | MAOAMAOBMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2021-01-28 | — | — | US | disclosed |
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2020-05-28 | — | — | US | disclosed |
| EP-3638678-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | Modernatx, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2019-10-03 | — | — | US | disclosed |
| US-10358433-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2019-07-23 | — | — | US | disclosed |
| US-20190047984-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2019-02-14 | — | — | US | disclosed |
| WO-2018232120-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
| US-10138220-B1 | Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2018-11-27 | — | — | US | disclosed |
| EP-2119718-A1 | MACROCYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-20090264437-A1 | 4-Piperazinyl-Pyrimidine Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor | ABBOTT GMBH & CO. KG (DE) | 2009-10-22 | — | — | US | disclosed |
| WO-2008132679-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-06 | — | — | WO | disclosed |
| EP-1778684-A1 | 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D<sb>3</sb> RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-05-02 | — | — | EP | disclosed |
| US-20060115848-A1 | Nucleic acid end-labeling reagents | BLOKHIN ANDREI | 2006-06-01 | — | — | US | disclosed |
| WO-2006023381-A1 | PYRIMIDINONE COMPOUNDS | TAIGEN BIOTECHNOLOGY (TW) | 2006-03-02 | — | — | WO | disclosed |
| US-20060036093-A1 | Pyrimidinone compounds | TAIGEN BIOTECHNOLOGY | 2006-02-16 | — | — | US | disclosed |
| WO-2006015842-A1 | 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006014588-A2 | NUCLEIC ACID END-LABELING REAGENTS | MIRUS BIO CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060008830-A1 | Nucleic acid end-labeling reagents | SLATTUM PAUL M | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | MAOA 666/4885MAOB 523/4885TSHR 90/4885 |
| US-10138220-B1 | Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | MAOA 842/4885MAOB 735/4885TSHR 105/4885 |
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | MAOA 717/4885MAOB 605/4885TSHR 77/4885 |
| US-20090264437-A1 | 4-Piperazinyl-Pyrimidine Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor | ADRA1D, ADRA1A, ADRA2A | MAOA 147/4885MAOB 313/4885TSHR 102/4885 |
| US-20060115848-A1 | Nucleic acid end-labeling reagents | POLM, POLN, POLRMT | MAOA 2278/4885MAOB 1806/4885TSHR 2264/4885 |
| US-20060008830-A1 | Nucleic acid end-labeling reagents | POLM, POLN, POLRMT | MAOA 2278/4885MAOB 1806/4885TSHR 2264/4885 |
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | MAOA 579/4885MAOB 485/4885TSHR 193/4885 |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | MAOA 666/4885MAOB 523/4885TSHR 90/4885 |
| US-20060036093-A1 | Pyrimidinone compounds | CXCR3, CCR5, CXCR5 | MAOA 4111/4885MAOB 3157/4885TSHR 1139/4885 |
| US-20190047984-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | MAOA 656/4885MAOB 542/4885TSHR 115/4885 |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | MAOA 666/4885MAOB 523/4885TSHR 90/4885 |
| US-10358433-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | MAOA 705/4885MAOB 635/4885TSHR 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.